We are excited to announce an upcoming Pharmacy SIG RxCited Clinical Conundrums Roundtable on December 1st from 2-3 pm CST. This session will cover clinical safety and efficacy data, key points, challenges, and practical issues associated with treosulfan-based conditioning regimens for allogeneic transplantation. This will be a great opportunity to explore and discuss the latest advancements impacting HCT with your peers via chat or open dialogue Expect a lively, informal Q&A session moderated by members of the ASTCT Pharmacy SIG Research Subcommittee.  

Is treosulfan really a better or safer version of busulfan?  Stay tuned for this exciting webinar with a pharmacist-led discussion on the emerging use of treosulfan in adults and pediatrics! 

The ASTCT Pharmacy SIG November 2026 Journal Club will air on Wednesday, November 18 at 2 p.m. CT/3 p.m. ET. The webinar consists of two, 30-minute journal club presentations, which include 20 minutes for the presentation and 10 minutes for discussion and a Q & A session. In the September Journal Club session, Drs. Hosick and Robida will present two articles related to:

• CRISPR-Cas9 gene-edited allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in acute myeloid leukemia (AML)
• Azacitidine-venetoclax versus induction chemotherapy for the treatment of acute myeloid leukemia (AML)

Presenters & Articles:

Madeleine Hosick, PharmD

PGY-2 Pharmacy Resident

Duke University Hospital

Article: CRISPR−Cas9 CD33-delet hematopoietic cell transp gemtuzumab ozogamicin AML: a phase 1/2 trial

Olivia Robida, PharmD

PGY-2 Pharmacy Resident

The Ohio State University - Wexner Medical Center

Article: Azacitidine–Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia

Session Learning Objectives:

Upon completion of the activity, participants should be able to:

• List the most common post-hematopoietic cell transplantation (HCT) maintenance strategies and limitations of these standards of care. 
• Discuss the efficacy and clinical implications of Tremtelectogene empogeditemcel (trem-cel) for maintenance in acute myeloid leukemia after allogenic HCT.
• Recognize the risks and toxicities associated with CRISPR-edited gene products in general, and specifically trem-cel in post-HCT patients.
• Review up-front treatment options for newly diagnosed, induction-eligible acute myeloid leukemia (AML) and the rationale for testing azacitidine–venetoclax against standard intensive 7+3 induction chemotherapy.
• Describe the safety and efficacy of azacitidine–venetoclax versus intensive induction chemotherapy for event-free survival in the PARADIGM phase 2 trial.
• Discuss clinical utility and applicability of azacitidine–venetoclax as up-front therapy for induction-eligible AML.

ACCREDITED PROVIDER

This activity is jointly provided by The France Foundation and American Society for Transplantation and Cellular Therapy (ASTCT).

In support of improving patient care, this activity has been planned and implemented by The France Foundation and American Society for Transplantation and Cellular Therapy (ASTCT). The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CREDIT DESIGNATION

Pharmacists

This knowledge-based activity qualifies for 1.0 contact hour (0.10 CEU) of continuing pharmacy education credit. Please submit all evaluations and credit requests no later than 30 days after you complete this activity to ensure your credit fulfillment, as CE credit cannot be awarded past 60 days from the activity date. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service ([email protected]). 

All other healthcare professionals completing this course will be issued a statement of participation.

The full accreditation information for this session will be available soon.

The Best of CAR T at the 2026 Tandem Meetings webinar is the second in a two-part CAR T webinar series. This session will air on Wednesday, December 9 at 3:00pm ET/2:00pm CT and will highlight the ASTCT Spotlight Session The Role of CAR T Persistence in Therapeutic Efficacy from the 2026 Tandem Meetings of ASTCT and CIBMTR. The session is open and free to all ASTCT members and non-members. 

Presentations and Speakers:

CD28 or 4-1BB CAR T: Fitness, Persistence, and Tumor Resistance
Mohamad Hamieh, PhD- Weill Cornell Medicine

Genetic Approaches for Engineering Persistent CAR T Cells
Evan Weber, PhD- Children's Hospital of Philadelphia

Efficacy and Persistence of Allogenic CAR T Cells
Melody Smith, MD, PhD- Stanford University

Thank you to Johnson & Johnson and Legend Biotech for their generous support of this webinar series.

TP53 mutated MDS and AML represent some of the most difficult diseases to treat, with poor prognosis. Although allogeneic stem cell transplant has the potential to cure myeloid malignancies, cure rates in TP53 mutated disease are low, and the utility of transplant for such patients is controversial. In this webinar, we will use a case based approach to debate the best transplant approach (including no transplant) for older patients with TP53 mutated disease in different scenarios. 

Presented by the ASTCT Aging SIG

Speakers:

Mariam Nawas, MD, University of Chicago Medical Center 
Pashna Munshi, MD, University of Pennsylvania
Mohamed Sorror, MD, Fred Hutchinson Cancer Center
Jacqueline Garcia, MD, Dana-Farber Cancer Institute
Mikkael Sekeres, MD, University of Miami

Moderator:

Rebecca Olin, MD MSCE, University of California San Francisco

This session is designed for and open to all members of a multidisciplinary care team to attend.

Learning Objectives
• Recognize bronchiectasis as a potential manifestation of chronic pulmonary GVHD/bronchiolitis obliterans syndrome (BOS).
• Interpret imaging and pulmonary function findings in the context of chronic lung GVHD.
• Discuss therapeutic challenges in refractory pulmonary chronic GVHD and explore emerging treatment strategies.

Speakers
• Gregory Burg, MD; Cincinnati Children's Hospital, Department of Pulmonology
• Paul Guillerman, MD: Cincinnati Children's Hospital, Department of Radiology
• Pooja Khandelwal, MD: Cincinnati Children's Hospital, Department of Pediatric Hematology

The ASTCT Pharmacy SIG September 2026 Journal Club aired on Wednesday, September 23 at 2 p.m. CT/3 p.m. ET. The webinar consisted of two, 30-minute journal club presentations, which included 20 minutes for the presentation and 10 minutes for discussion and a Q & A session. In the September Journal Club session, Drs. Albuquerque and Bazaco presented two articles related to:

• B-cell depletion for prevention of corticosteroid-requiring cGVHD
• Fludarabine vs Bendamustine as a lymphodepleting chemotherapy prior to CAR-T for large cell lymphoma 

Presenters & Articles:

Esther Albuquerque, PharmD

PGY-2 Pharmacy Resident

The James Cancer Hospital at the Ohio State University 

Article: Randomized, Placebo-Controlled Trial of B-Cell Depletion for Prevention of Corticosteroid-Requiring Chronic Graft-Versus-Host Disease

Christopher Bazaco, PharmD

PGY-2 Pharmacy Resident

Inova Health

Article: Comparison of Fludarabine Versus Bendamustine as a Lymphodepleting Chemotherapy Prior to CAR-T for Large Cell Lymphoma

Session Learning Objectives:

Upon completion of the activity, participants should be able to:

• Review the role of B cells in the development of chronic graft-versus-host disease (cGVHD) following allogeneic hematopoietic stem cell transplantation
• Analyze the efficacy and safety of prophylactic obinutuzumab for the prevention of corticosteroid-requiring cGVHD
• Discuss the utility of B-cell depletion as a cGVHD prevention strategy and the potential role of H-Y antibody status in identifying patients that will most likely benefit
• Compare efficacy outcomes between fludarabine-based and bendamustine-based lymphodepletion (LD) prior to CD19 CAR-T therapy in large B-cell lymphoma
• Evaluate the toxicity profiles associated with each LD regimen, including rates of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), prolonged cytopenia, and treatment-related mortality
• Identify clinical factors influencing CAR-T outcomes such as CAR-T product type, disease status, KPA, bridging therapy, and patient age
• Recognize when bendamustine may serve as a practical alternative LD regimen for DLBCL patients

This activity will expire on September 22, 2027.

ACCREDITED PROVIDER

This activity is jointly provided by The France Foundation and American Society for Transplantation and Cellular Therapy (ASTCT).

In support of improving patient care, this activity has been planned and implemented by The France Foundation and American Society for Transplantation and Cellular Therapy (ASTCT). The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CREDIT DESIGNATION

Pharmacists

This knowledge-based activity qualifies for 1.0 contact hour (0.10 CEU) of continuing pharmacy education credit. Please submit all evaluations and credit requests no later than 30 days after you complete this activity to ensure your credit fulfillment, as CE credit cannot be awarded past 60 days from the activity date. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service ([email protected]). 

All other healthcare professionals completing this course will be issued a statement of participation.

The full accreditation information for this enduring session can be found here. 

WEBINAR 1: Patient Selection and Comparative Regimen Review (30 minutes)
This session addresses the critical decision-making process in conditioning regimen selection. Faculty will outline criteria for identifying appropriate candidates for reduced-toxicity conditioning versus myeloablative approaches, followed by a comprehensive review of current reduced-toxicity regimens. The presentation compares efficacy outcomes and safety profiles across regimens, with direct application to clinical practice through a complex AML/MDS case presentation that demonstrates real-world decision-making principles.

WEBINAR 2: Prevention and Monitoring Strategies for Treatment-Related Adverse Events (30 minutes)
This session focuses on proactive approaches to minimize complications associated with reduced-toxicity conditioning. Faculty will present strategies for pre-transplant risk assessment, evidence-based monitoring protocols, prevention strategies, and structured management algorithms for key complications that may arise during and after conditioning.

WEBINAR 3: Interactive Case Discussion and Clinical Application (30 minutes)
This session reinforces learning through interactive case-based discussion. Faculty will guide participants through complex clinical scenarios, highlighting how to apply patient selection criteria, choose appropriate regimens, and implement monitoring and management strategies in real-world settings. The session concludes with expert commentary on emerging best practices and evolving approaches to optimizing patient outcomes.

Additional information regarding speakers and accreditation can be found within each webinar.

This educational program was made possible through a generous educational grant from Medexus.

The Medicare Rules Round-up Webinar was on Wednesday, August 19, 2026 from 11:00 a.m. – 12:00 p.m. CDT with Director of Government Relations, Molly Ford, and the reimbursement and policy advisors from Nimitt Consulting.

The OPPS and MPFS proposed rules were released on July 7 and July 16, respectively. ASTCT circulated draft comments to CMS in advance of the comment period closing.  Comments can be submitted to CMS via https://www.regulations.gov and are due by August 31 (OPPS) and September 14 (MPFS).

The IPPS final rule was issued on July 31 and goes into effect on October 1, 2026.  A few payment highlights include the following:

• Overall payments were increased by 2.3%
• The base payment for MS-DRG 014 (Allogeneic Stem Cell Transplant) decreased slightly from FY 2026 to $87,109
• The base payment for MS-DRG 018 (CAR-T and Other Immunotherapies) has increased by almost $20,000 to $333,445
• The outlier fixed loss threshold has increased to $49,346 per MS-DRG, up from $40,397

Please consider sharing this webinar information with your network of physicians, administrators, providers, or any other colleagues that may be interested.

The Cord Blood as Graft of Choice for Difficult-to-Cure Acute Leukemia webinar, presented by the ASTCT Cord Blood SIG, aired on Wednesday, July 1 at 11 a.m. CT/12 p.m. ET. The speakers participated in a moderated roundtable discussion, focusing on the state-of-the-art in cord blood transplantation in high-risk disease settings, the future research and work needed.

Session Description:

The Cord blood transplantation is associated with robust graft-versus-leukemia effect, and recent data from centers with cord blood transplantation expertise have shown outstanding post-transplant outcomes, including for patients with high-risk hematologic malignancies. This webinar continues the conversation following a spotlight session hosted by the ASTCT Cord Blood SIG at Tandem 2026 on the cord blood transplantation for patients with high risk hematologic malignancies. The session will review cord blood transplantation outcome data from multiple institutions across three continents and with different patient populations, highlighting the special value of cord blood transplantation in adult and pediatric patients to mitigate disease relapse and improve transplant outcomes. The speakers will participate in a moderated roundtable discussion, focusing on the state-of-the-art in cord blood transplantation in high-risk disease settings, the future research and work needed.

Presenters:

Juliet Barker, MBBS

New York-Presbyterian/Weill Cornell Medical Center; New York City, NY

Filippo Milano, MD, PhD

Fred Hutchinson Cancer Center, University of Washington; Seattle, WA

Robert Wynn, MD, MRCP

Royal Manchester Children's Hospital; Manchester, UK

Moderator:

Warren Fingrut, MD, MPH

The University of Texas MD Anderson Cancer Center; Houston, TX

Session Learning Objectives:

Upon completion of the activity, participants should be able to:

• Understand the indications for cord blood transplantation
• Synthesize cord blood transplantation outcomes data, including in high risk disease settings, from multiple centers with cord blood transplantation expertise
• Review translational work underlying the unique graft-versus-leukemia biology in cord blood transplantation.

The ASTCT Pharmacy SIG June 2026 Journal Club aired on Wednesday, June 10. The webinar consisted of two, 30-minute journal club presentations, which included 20 minutes for the presentation and 10 minutes for discussion and a Q & A session. In the June Journal Club session, Drs. Dugas and Kanchan presented two articles related to:

• Brexucabtagene autoleucel in BTKi‑naive relapsed/refractory mantle cell lymphoma
• Carfilzomib, lenalidomide, and dexamethasone vs lenalidomide maintenance post‑transplant in multiple myeloma

Presenters & Articles:

Logan Dugas, PharmD

PGY-2 Pharmacy Resident

Moffitt Cancer Center

Article: Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial

Nidhi Kanchan, PharmD

PGY-2 Pharmacy Resident

UC San Diego Health

Article: Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 cohort 3

Session Learning Objectives:

Upon completion of the activity, participants should be able to:

• Recognize post-ASCT maintenance strategies that have been studied in multiple myeloma.
• Report efficacy and safety of KRd as a risk-stratified maintenance approach.
• Discuss the application of KRd maintenance following transplant in newly diagnosed multiple myeloma.
• Review current treatment recommendations and sequencing of therapy for relapsed/refractory mantle cell lymphoma, including the role of BTK inhibitors.
• Evaluate safety and efficacy of brexucabtagene autoleucel in BTKi-naive patients with relapsed/refractory mantle cell lymphoma based on the primary analysis of ZUMA-2 Cohort 3.
• Summarize the role of brexucabtagene autoleucel in earlier lines of therapy for patients with high-risk relapsed/refractory mantle cell lymphoma.

This activity will expire on June 9, 2027.

ACCREDITED PROVIDER

This activity is jointly provided by The France Foundation and American Society for Transplantation and Cellular Therapy (ASTCT).

In support of improving patient care, this activity has been planned and implemented by The France Foundation and American Society for Transplantation and Cellular Therapy (ASTCT). The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CREDIT DESIGNATION

Pharmacists

This knowledge-based activity qualifies for 1.0 contact hour (0.10 CEU) of continuing pharmacy education credit. Please submit all evaluations and credit requests no later than 30 days after you complete this activity to ensure your credit fulfillment, as CE credit cannot be awarded past 60 days from the activity date. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service ([email protected]). 

All other healthcare professionals completing this course will be issued a statement of participation.

The full accreditation information for this session can be found here.